Cargando…
Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study
Iron deficiency (ID) impairs hemoglobin (Hb) synthesis and immune function, both crucial for sepsis patients. We assessed the impact of iron dextran on reticulocyte (Ret) Hb equivalent (Ret-He) and Ret subpopulations in iron-deficient sepsis patients. In this prospective clinical study we enrolled p...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066317/ https://www.ncbi.nlm.nih.gov/pubmed/37002279 http://dx.doi.org/10.1038/s41598-023-32002-y |
_version_ | 1785018261676490752 |
---|---|
author | Czempik, Piotr F. Wiórek, Agnieszka |
author_facet | Czempik, Piotr F. Wiórek, Agnieszka |
author_sort | Czempik, Piotr F. |
collection | PubMed |
description | Iron deficiency (ID) impairs hemoglobin (Hb) synthesis and immune function, both crucial for sepsis patients. We assessed the impact of iron dextran on reticulocyte (Ret) Hb equivalent (Ret-He) and Ret subpopulations in iron-deficient sepsis patients. In this prospective clinical study we enrolled patients with sepsis or septic shock with procalcitonin concentration > 0.5 ng/mL, diagnosed with ID based on Ret-He. Study subjects received divided doses of iron dextran until normalization of Ret-He. The study population included 35 subjects. The median Ret-He increase after 2 doses of iron dextran was 3.0 (IQR 1.9–6.1) pg (p < 0.01) with median time to normalization 4 (IQR 3–5) days. Although no change in Ret percentage [Me 1.5 (IQR 1.1–2.1) vs. Me 1.4 (IQR 1.1–2.4) %, p = 0.39] and number [Me 0.05 (IQR 0.04–0.07) vs. Me 0.05 (IQR 0.03–0.06) 10(6)/µL, p = 0.88] was noted, Ret subpopulations changed significantly (p for all < 0.01). Divided doses of iron dextran relatively quickly normalize Ret-He in iron-deficient sepsis patients. Changes in Ret subpopulations suggest increased erythropoietic activity. Further research is needed to explore the role of intravenous iron in this clinical setting. |
format | Online Article Text |
id | pubmed-10066317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100663172023-04-02 Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study Czempik, Piotr F. Wiórek, Agnieszka Sci Rep Article Iron deficiency (ID) impairs hemoglobin (Hb) synthesis and immune function, both crucial for sepsis patients. We assessed the impact of iron dextran on reticulocyte (Ret) Hb equivalent (Ret-He) and Ret subpopulations in iron-deficient sepsis patients. In this prospective clinical study we enrolled patients with sepsis or septic shock with procalcitonin concentration > 0.5 ng/mL, diagnosed with ID based on Ret-He. Study subjects received divided doses of iron dextran until normalization of Ret-He. The study population included 35 subjects. The median Ret-He increase after 2 doses of iron dextran was 3.0 (IQR 1.9–6.1) pg (p < 0.01) with median time to normalization 4 (IQR 3–5) days. Although no change in Ret percentage [Me 1.5 (IQR 1.1–2.1) vs. Me 1.4 (IQR 1.1–2.4) %, p = 0.39] and number [Me 0.05 (IQR 0.04–0.07) vs. Me 0.05 (IQR 0.03–0.06) 10(6)/µL, p = 0.88] was noted, Ret subpopulations changed significantly (p for all < 0.01). Divided doses of iron dextran relatively quickly normalize Ret-He in iron-deficient sepsis patients. Changes in Ret subpopulations suggest increased erythropoietic activity. Further research is needed to explore the role of intravenous iron in this clinical setting. Nature Publishing Group UK 2023-03-31 /pmc/articles/PMC10066317/ /pubmed/37002279 http://dx.doi.org/10.1038/s41598-023-32002-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Czempik, Piotr F. Wiórek, Agnieszka Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study |
title | Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study |
title_full | Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study |
title_fullStr | Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study |
title_full_unstemmed | Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study |
title_short | Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study |
title_sort | iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066317/ https://www.ncbi.nlm.nih.gov/pubmed/37002279 http://dx.doi.org/10.1038/s41598-023-32002-y |
work_keys_str_mv | AT czempikpiotrf irondeficiencyinsepsispatientsmanagedwithdivideddosesofirondextranaprospectivecohortstudy AT wiorekagnieszka irondeficiencyinsepsispatientsmanagedwithdivideddosesofirondextranaprospectivecohortstudy |